SG11202106209RA - Bifunctional molecules for lysosomal targeting and related compositions and methods - Google Patents

Bifunctional molecules for lysosomal targeting and related compositions and methods

Info

Publication number
SG11202106209RA
SG11202106209RA SG11202106209RA SG11202106209RA SG11202106209RA SG 11202106209R A SG11202106209R A SG 11202106209RA SG 11202106209R A SG11202106209R A SG 11202106209RA SG 11202106209R A SG11202106209R A SG 11202106209RA SG 11202106209R A SG11202106209R A SG 11202106209RA
Authority
SG
Singapore
Prior art keywords
methods
related compositions
bifunctional molecules
lysosomal targeting
lysosomal
Prior art date
Application number
SG11202106209RA
Inventor
Carolyn Bertozzi
Steven Banik
Kayvon Pedram
Green Ahn
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of SG11202106209RA publication Critical patent/SG11202106209RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
SG11202106209RA 2018-12-19 2019-12-18 Bifunctional molecules for lysosomal targeting and related compositions and methods SG11202106209RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862782193P 2018-12-19 2018-12-19
US201962932347P 2019-11-07 2019-11-07
PCT/US2019/067228 WO2020132100A1 (en) 2018-12-19 2019-12-18 Bifunctional molecules for lysosomal targeting and related compositions and methods

Publications (1)

Publication Number Publication Date
SG11202106209RA true SG11202106209RA (en) 2021-07-29

Family

ID=71102305

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106209RA SG11202106209RA (en) 2018-12-19 2019-12-18 Bifunctional molecules for lysosomal targeting and related compositions and methods

Country Status (12)

Country Link
US (3) US20220023434A1 (en)
EP (1) EP3897747A4 (en)
JP (1) JP2022513299A (en)
KR (1) KR20210104828A (en)
CN (1) CN113301925A (en)
AU (1) AU2019404061A1 (en)
BR (1) BR112021012113A2 (en)
CA (1) CA3123086A1 (en)
IL (1) IL283958A (en)
MX (1) MX2021007376A (en)
SG (1) SG11202106209RA (en)
WO (1) WO2020132100A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019404061A1 (en) 2018-12-19 2021-07-22 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules for lysosomal targeting and related compositions and methods
CN115315272A (en) * 2019-10-10 2022-11-08 耶鲁大学 Targeting difunctional degradation agent
MX2022009419A (en) 2020-01-31 2022-08-25 Avilar Therapeutics Inc Asgpr-binding compounds for the degradation of extracellular proteins.
AU2021225962A1 (en) 2020-02-28 2022-10-20 Genzyme Corporation Modified binding polypeptides for optimized drug conjugation
EP4172188A1 (en) * 2020-06-30 2023-05-03 The Board of Trustees of the Leland Stanford Junior University Cis-binding siglec agonists and related compositions and methods
WO2022035997A1 (en) * 2020-08-11 2022-02-17 Avilar Therapeutics, Inc. In vivo assembly of asgpr binding therapeutics
CN114438088A (en) * 2020-11-03 2022-05-06 韩达 Preparation and application of lysosome-targeted nucleic acid chimera
JP2024503687A (en) * 2021-01-19 2024-01-26 ノバルティス アーゲー Degradation of extracellular targets
WO2022194078A1 (en) * 2021-03-15 2022-09-22 北京大学 Conjugate for target molecule modification and preparation method therefor
CN117321077A (en) * 2021-04-02 2023-12-29 小利兰·斯坦福大学理事会 Bispecific molecules and related compositions and methods
KR20240017423A (en) * 2021-05-03 2024-02-07 아빌라 테라퓨틱스, 인크. Potent ASGPR-binding compound for degradation of immunoglobulins and other proteins
WO2022271981A2 (en) * 2021-06-23 2022-12-29 Lycia Therapeutics, Inc. Bifunctional compounds containing igf-2 polypeptides
WO2023288015A1 (en) 2021-07-14 2023-01-19 Lycia Therapeutics, Inc. M6pr cell surface receptor binding compounds and conjugates
WO2023016828A2 (en) 2021-07-30 2023-02-16 Vib Vzw Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
CN117343197A (en) * 2021-10-15 2024-01-05 中山大学 Recombinant fusion antibodies
CN114522244B (en) * 2022-01-28 2023-09-01 浙江大学医学院附属第四医院 Retinoic acid modified LYTAC molecule, and preparation method and application thereof
FR3132634A1 (en) * 2022-02-15 2023-08-18 Nanomedsyn Bifunctional compounds targeting the cation-independent mannose 6-phosphate receptor
WO2023178202A2 (en) * 2022-03-15 2023-09-21 Yale University Bifunctional small molecules to target the selective degradation of circulating proteins
WO2023178179A2 (en) * 2022-03-15 2023-09-21 Yale University Bi-functional molecules to degrade circulating proteins
WO2023183413A2 (en) * 2022-03-22 2023-09-28 Wisconsin Alumni Research Foundation Transferrin-based lysosome targeting degraders
WO2023247754A1 (en) * 2022-06-23 2023-12-28 Draupnir Bio Aps Bifunctional molecules that selectively induce degradation of extracellular targets in lysosomes
WO2024003300A1 (en) * 2022-06-30 2024-01-04 Aptadegrad, S.L. Dna aptamer conjugates recognizing and degrading coronavirus proteins
GB202211100D0 (en) * 2022-07-29 2022-09-14 Stam Jord Cornelis Lysosomal degradation
GB202212077D0 (en) 2022-08-18 2022-10-05 Tribune Therapeutics Ab Agents that inhibit ccn ligand-induced signalling for treating disease
WO2024068768A1 (en) * 2022-09-28 2024-04-04 Glycoera Ag Glycoengineering using leishmania cells

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993006216A1 (en) 1991-09-26 1993-04-01 Oklahoma Medical Research Foundation Fusion proteins targeted to lysosomes, for the treatment of aids
DK129293D0 (en) 1993-11-16 1993-11-16 Carlsberg Lab CARBOHYDRATE-CONTAINING COMPOUNDS THAT CAN BE BINDED TO CARBOHYDRATE-BINDING RECEPTORS
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
AU2662999A (en) * 1998-02-09 1999-08-23 Genzyme Corporation Nucleic acid delivery vehicles
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
EP1117443B1 (en) 1998-10-08 2005-11-02 Stichting voor de Technische Wetenschappen Peptide-based carrier devices for stellate cells
US6426208B1 (en) 1999-11-12 2002-07-30 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US20040009907A1 (en) 2001-02-26 2004-01-15 Alsobrook John P. Proteins and nucleic acids encoding same
JP2004506408A (en) * 2000-04-26 2004-03-04 イルーシス　セラポーティクス，インコーポレーテッド Bispecific molecules and their uses
EP1399435A2 (en) 2000-09-01 2004-03-24 Biogen, Inc. Pyridine derivatives useful as cd40:cd154 binding interruptors and use thereof to treat immunological complications
ES2404689T3 (en) 2001-04-05 2013-05-28 The Johns Hopkins University Chimeric vaccines comprising the lumenal domain of LAMP-1 or LAMP-2
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20030049203A1 (en) 2001-08-31 2003-03-13 Elmaleh David R. Targeted nucleic acid constructs and uses related thereto
ES2411007T3 (en) * 2001-10-10 2013-07-04 Novo Nordisk A/S Remodeling and glycoconjugation of peptides
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7485314B2 (en) 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
US20050191309A1 (en) 2002-05-06 2005-09-01 Kakkis Emil D. Induction of antigen specific immunologic tolerance
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
CA2525328C (en) 2003-05-20 2012-07-31 Pharmaxis Pty Ltd. Novel phosphotetrahydropyrans and methods
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
WO2006007560A2 (en) 2004-07-01 2006-01-19 University Of Pennsylvania Targeted protein replacement for the treatment of lysosomal storage disorders
GB0423405D0 (en) 2004-10-21 2004-11-24 Novartis Ag Organic compounds
EP1745802A1 (en) 2005-07-20 2007-01-24 Kreatech Biotechnology B.V. Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes
US20070104648A1 (en) 2005-11-09 2007-05-10 Glyconix Corporation Compositions, methods of preparing amino acids, and nuclear magnetic resonance spectroscopy
CA2649182C (en) 2006-04-07 2018-01-02 The Board Of Regents Of The University Of Texas System Methods and compositions related to adenoassociated virus-phage particles
US20080057072A1 (en) 2006-08-31 2008-03-06 Alcon Manufacturing, Ltd. Antagonists of ci-m6p/igf2r for prevention and treatment of ctgf-mediated ocular disorders
BRPI0718651B8 (en) 2006-11-10 2021-05-25 Cara Therapeutics Inc synthetic peptide amides
WO2008089339A2 (en) * 2007-01-18 2008-07-24 Genzyme Corporation Oligosaccharide conjugates for cellular targeting
NZ592255A (en) 2008-09-17 2013-07-26 Endocyte Inc Folate receptor binding conjugates of antifolates
SG175816A1 (en) 2009-04-28 2011-12-29 Pharmaxis Pty Ltd Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders
EP2448600B1 (en) * 2009-07-03 2016-03-30 INSERM - Institut National de la Santé et de la Recherche Médicale Compounds targeting the cation-independent mannose 6-phosphate receptor
EP2480235A4 (en) 2009-09-24 2013-05-08 Univ Louisville Res Found Novel iodo pyrimidine derivatives useful for the treatment of macrophage migration inhibitory factor (mif)-implicated diseases and conditions
FR2952372B1 (en) 2009-11-10 2012-03-23 Centre Nat Rech Scient NOVEL MANNOPYRANOSIDE DERIVATIVES WITH ANTICANCER ACTIVITY
EP2343081A1 (en) 2009-12-31 2011-07-13 Rijksuniversiteit Groningen Interferon analogs
US20120121592A1 (en) * 2010-10-13 2012-05-17 Baylor Research Institute Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells
EP2714752B1 (en) 2011-05-27 2017-11-22 Amicus Therapeutics, Inc. Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases
PL2825553T3 (en) * 2012-03-14 2018-12-31 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
WO2014022515A1 (en) 2012-07-31 2014-02-06 Bioasis Technologies, Inc. Dephosphorylated lysosomal storage disease proteins and methods of use thereof
WO2014082080A2 (en) 2012-11-26 2014-05-30 Callidus Biopharma, Inc. Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases
JP2016501881A (en) 2012-12-04 2016-01-21 アッヴィ・インコーポレイテッド Bispecific binding protein that permeates the blood-brain barrier (BBB)
EP2981551B1 (en) 2013-02-20 2020-06-03 Valerion Therapeutics, LLC Methods and compositions for treatment of pompe disease
JP6473138B2 (en) 2013-05-03 2019-02-20 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ Synthetic antibody mimetic compounds (SyAM) targeting cancer, particularly prostate cancer
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
TWI641620B (en) 2013-08-21 2018-11-21 再生元醫藥公司 Anti-prlr antibodies and uses thereof
PT3129067T (en) 2014-03-19 2023-03-22 Genzyme Corp Site-specific glycoengineering of targeting moieties
PL3145934T3 (en) 2014-05-19 2021-08-16 Pfizer Inc. Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of asgpr
WO2015191934A2 (en) 2014-06-11 2015-12-17 Abbvie Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
CA2956469A1 (en) * 2014-08-11 2016-02-18 Shire Human Genetic Therapies, Inc. Mannose-6-phosphate bearing peptides fused to lysosomal enzymes
WO2016040305A1 (en) 2014-09-08 2016-03-17 Temple University-Of The Commonwealth System Of Higher Education Pcsk9 inhibitors and methods of use thereof
MX2017004664A (en) 2014-10-09 2017-06-30 Genzyme Corp Glycoengineered antibody drug conjugates.
US20160166679A1 (en) 2014-12-12 2016-06-16 Purdue Research Foundation Method of treatment using folate conjugates and tyrosine kinase inhibitors
EP3722318A1 (en) * 2015-07-06 2020-10-14 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
FR3041345B1 (en) 2015-09-18 2019-06-14 Nanomedsyn MULTI-FUNCTIONALIZED POLYSACCHARIDE COMPOUNDS AND THEIR USE FOR TARGETING THE CATION-INDEPENDENT MAN-6-PHOSPHATE RECEPTOR
AU2016332900C1 (en) * 2015-09-29 2024-02-01 Amgen Inc. ASGR inhibitors
NZ743008A (en) 2015-12-08 2023-05-26 Regeneron Pharma Compositions and methods for internalizing enzymes
AU2017214338B2 (en) * 2016-02-05 2024-04-11 Genmab A/S Multispecific antigen-binding molecule with improved internalization characteristics
US11865185B2 (en) 2016-06-09 2024-01-09 Centre National De La Recherche Scientifique (Cnrs) RAAV with chemically modified capsid
CN110809583A (en) 2017-06-07 2020-02-18 瑞泽恩制药公司 Compositions and methods for internalizing enzymes
WO2019199634A1 (en) 2018-04-09 2019-10-17 Yale University Bifunctional small molecules to target the selective degradation of circulating proteins
CA3134765A1 (en) 2018-04-09 2019-10-17 Yale University Bi-functional molecules to degrade circulating proteins
AU2019404061A1 (en) 2018-12-19 2021-07-22 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules for lysosomal targeting and related compositions and methods
FI3997214T3 (en) 2019-07-11 2023-11-02 Centre Nat Rech Scient Chemically-modified adeno-associated virus
CN115315272A (en) 2019-10-10 2022-11-08 耶鲁大学 Targeting difunctional degradation agent
EP4041313A4 (en) 2019-10-10 2024-01-10 Univ Yale Engineered antibodies as molecular degraders through cellular receptors

Also Published As

Publication number Publication date
CA3123086A1 (en) 2020-06-25
CN113301925A (en) 2021-08-24
KR20210104828A (en) 2021-08-25
EP3897747A1 (en) 2021-10-27
MX2021007376A (en) 2021-09-21
US11787865B2 (en) 2023-10-17
BR112021012113A2 (en) 2021-09-08
WO2020132100A1 (en) 2020-06-25
US20230416377A1 (en) 2023-12-28
JP2022513299A (en) 2022-02-07
US20220025057A1 (en) 2022-01-27
IL283958A (en) 2021-07-29
EP3897747A4 (en) 2022-12-07
AU2019404061A1 (en) 2021-07-22
US20220023434A1 (en) 2022-01-27

Similar Documents

Publication Publication Date Title
IL283958A (en) Bifunctional molecules for lysosomal targeting and related compositions and methods
SG11202001208XA (en) Rna targeting methods and compositions
IL265086A (en) Methods and compositions for targeting t-cell cancers
EP3574018A4 (en) Tumor targeting conjugates and methods of use thereof
EP3380126A4 (en) Antibody-drug conjugates comprising branched linkers and methods related thereto
PH12016502142B1 (en) Anti-ptk7 antibody-drug conjugates
EP3575319A4 (en) Bifunctional molecule and use thereof
HUE049291T2 (en) Antibody-drug conjugates and immunotoxins
EP3707257A4 (en) Methods and compositions for circular rna molecules
IL266690A (en) Substances for targeting various selected organs or tissues
EP3737391A4 (en) Compositions and methods for targeting cd99-expressing cancers
PL3102606T3 (en) Antibody-drug conjugates and immunotoxins
EP3215163A4 (en) Beta-glucan methods and compositions that affect the tumor microenvironment
EP3655440A4 (en) Compositions and methods for targeting cd33-expressing cancers
EP3710039A4 (en) Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
EP3630090A4 (en) Combination therapy for cancer using botanical compositions and enzalutamide
EP3271399A4 (en) Compositions and methods for targeting cd99 in haematopoietic and lymphoid malignancies
HK1258338A1 (en) Antibody-drug conjugates targeting uparap
EP3897680A4 (en) Compositions and methods useful for targeting the blood-brain barrier
IL262347A (en) Sugar-dipeptide conjugates as flavor molecules
IL262099B (en) Sugar-dipeptide conjugates as flavor molecules
EP3600420A4 (en) Tumor necrosis targeting compositions and methods
IL287917A (en) Hyaluronan conjugates and uses thereof
IL262096A (en) Sugar-dipeptide conjugates as flavor molecules